Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2023 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

Preclinical Posters to Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the Next Generation AlloCAR T™ Platform Cloak ™ and Dagger™ Technologies Highlighted Potential...
November 02, 2023 09:00 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Comprehensive Review of Overall Treatment Safety Profile of our ALLO-501/501A Candidate Used in Conjunction with Propriety Lymphodepletion with Investigational ALLO-647 from the Phase 1 ALPHA/ALPHA2...
October 30, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
October 26, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
October 16, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
September 27, 2023 09:09 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate...
September 05, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in September Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
August 14, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Appoints Earl Douglas as General Counsel

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
August 02, 2023 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and...
July 26, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...